Reuters logo
BRIEF-Oradur-Methylphenidate ER capsule achieves primary endpoint in Phase 3 study in ADHD in Taiwan
2017年8月8日 / 下午12点41分 / 2 个月前

BRIEF-Oradur-Methylphenidate ER capsule achieves primary endpoint in Phase 3 study in ADHD in Taiwan

Aug 8 (Reuters) - Durect Corp

* Oradur-Methylphenidate ER capsule achieves primary endpoint in Phase 3 study in ADHD in Taiwan

* Durect Corp - ‍study drug was generally safe and well tolerated​

* Durect Corp - ‍there were no serious adverse events in pivotal study​

* Durect Corp - ‍for primary efficacy endpoint, Oradur-Methylphenidate ER capsule was superior to placebo in a statistically significant manner​

* Durect - announced Orient Pharma has informed co that Phase 3 clinical study of Oradur-Methylphenidate ER capsule conducted in Taiwan has achieved positive results​ Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below